Research
Hormonal
Daily oral orforglipron was associated with a mean weight reduction ranging from -8.6% to -12.6% at week 26 and -9.4% to -14.7% at week 36 in participants receiving the drug.
Orforglipron may be an effective oral treatment option for weight reduction in adults with obesity.
StrongSupportsmedium confidence
At week 26, the mean change from baseline in body weight ranged from -8.6% to -12.6% across the orforglipron dose cohorts and was -2.0% in the placebo group. At week 36, the mean change ranged from -9.4% to -14.7% with orforglipron and was -2.3% with placebo.
Why this rating
Based on the phase 2 randomized, double-blind trial design.
Source
Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity
Sean Wharton et al. · New England Journal of Medicine · 2023
rct · n=272Cited 412×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →